Please enable Javascript
An official publication of
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Leah Lawrence
Leah Lawrence is a freelance health writer and editor based in Delaware.
Articles by Leah Lawrence
Status Update: MRD Continues to Prove Utility in Hematologic Malignancies
Leah Lawrence
Print
|
November 18, 2024
The interest in using quantitative tests to measure residual cancer cells continues to expand in the arena of blood cancers.
Read More
Unpacking CHIP: Recent Updates, Remaining Questions
Leah Lawrence
Print
|
October 8, 2024
While research on CHIP has gained momentum in recent years, treating the premalignant condition remains in debate.
Read More
Making Headway in MDS: Two Novel Agents for Advanced Lower-Risk MDS Treatment
Leah Lawrence
Print
|
August 26, 2024
Following FDA approval, luspatercept and imetelstat are propelling the MDS treatment landscape forward.
Read More
CAR T-Cell Therapies Remain Worth the Risk
Leah Lawrence
Transplantation & Cellular Therapy
|
May 22, 2024
Benefits of CAR T-cell therapy outweigh the hypothetical future risk of secondary malignancies.
Read More
Prognostic Value of CLL-IPI Diminished in Targeted Therapy Era
Leah Lawrence
Chronic Lymphocytic Leukemia
|
May 17, 2024
A new evaluation of the CLL-IPI revealed that its impact appears diminished in predicting OS in the era of targeted drugs.
Read More
Epigenetic Signature Could Improve Prediction of MBL Progression
Leah Lawrence
Chronic Lymphocytic Leukemia
|
May 17, 2024
The ELCLV3-21 high-risk signature distinguished those with MBL with a high probability of progression.
Read More
T-Bet Suppresses Proliferation of Malignant B Cells in CLL
Leah Lawrence
Chronic Lymphocytic Leukemia
|
August 23, 2024
In single-cell resolved multi-omics analyses, T-bet expression in CLL cells correlated with longer overall patient survival.
Read More
What’s Old Is New: Old Technology Finds New Application in Plasma Cell Disorder Management
Leah Lawrence
Myeloma
|
February 8, 2024
Researchers are working to define and validate the ways in which mass spectrometry can aid in MM diagnosis and monitoring.
Read More
Why Are Generic Cancer Drugs Out of Reach for Many Patients?
Leah Lawrence
Print
|
January 4, 2024
Shortages of essential drugs are not new, with one expert describing it as a “whack-a-mole” problem.
Read More
Molecular IPSS Adds No Prognostic Power for HMA-Treated MDS
Leah Lawrence
Myelodysplastic Syndromes
|
December 13, 2023
OS was still inversely proportional to the IPSS-M, but the molecular risk stratification had no additional prognostic power.
Read More
String of Recent Approvals Puts Spotlight on Bispecifics
Leah Lawrence
Transplantation & Cellular Therapy
|
February 8, 2024
Here’s what they add to the treatment toolbox for hematologic malignancies.
Read More
How Can We Challenge the Status Quo in Myeloma Research?
Leah Lawrence
Myeloma
|
February 8, 2024
Researchers and clinicians are attempting to make clinical trials better reflect the population of patients with MM.
Read More
First-line Selinexor, Ruxolitinib Shows Ongoing Promise for Myelofibrosis
Leah Lawrence
Myelofibrosis
|
February 8, 2024
Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting.
Read More
Luspatercept Improved Anemia, Transfusion Burden in Myelofibrosis
Leah Lawrence
Myelofibrosis
|
February 8, 2024
The open-label ACE-536-MF-001 study included patient cohorts grouped by transfusion dependance and ruxolitinib therapy.
Read More
Pacritinib Spleen Response Yielded OS Benefit in Cytopenic Myelofibrosis
Leah Lawrence
Myelofibrosis
|
September 18, 2023
In PERSIST-2, treatment with pacritinib demonstrated a significant SVR benefit compared with the best available therapy, incl
Read More
Event-free Survival at 24 Months in MCL Yielded Expected OS of General Population
Leah Lawrence
Mantle Cell Lymphoma
|
September 10, 2023
Achieving event-free survival at 24 months using modern treatments was associated with improved OS.
Read More
Questions Remain About Role of Hypoxia Related to NHL CAR T-cell Therapy
Leah Lawrence
Meeting News
|
September 10, 2023
Intratumoral hypoxia could be associated with CAR-T outcomes in patients with non-Hodgkin lymphoma.
Read More
Data on T-cell Exhaustion Support Earlier Use of T-cell-based Therapies in Splenic MZL
Leah Lawrence
Meeting News
|
September 10, 2023
The composition of T cells in patients with sMZL may affect the efficacy of T-cell-based therapies.
Read More
Shorter Duration Induction Venetoclax Feasible for Older, Unfit AML
Leah Lawrence
Acute Lymphoblastic Leukemia
|
September 6, 2023
This single-center retrospective study looked at outcomes from 18 patients with AML treated with venetoclax plus an HMA.
Read More
T-Cell ALL Overall Survival Differed by Ethnicity, Small Study Showed
Leah Lawrence
Meeting News
|
September 6, 2023
The study included 59 patients with T-ALL with a median age of 20 at diagnosis.
Read More
Load More